

**A Phase III double-blind placebo-controlled  
randomized trial of aspirin on recurrence and  
survival in colon cancer patients**



**Pharmacy protocol**  
(English version)

## **Administrative responsibilities**

### **Principal investigator**

Prof. dr. Marc Peeters, Dept. Oncology, UZA Antwerpen

### **Central study coordinator**

M. De Roose

University hospital Antwerp

MOCA

Wilrijkstraat 10, 2650 Edegem

Phone +32 3 821 40 82

Fax +32 3 825 15 92

E-mail [aspirin@uza.be](mailto:aspirin@uza.be)

G. Vanhoutte (back-up)

Phone +32 3 821 52 74


L. De Backer (back-up)

Phone +32 3 821 52 75

## Content

1.	Randomisation procedure .....	4
2.	Randomisation.....	5
	2.1 Randomisation/ confirmation email .....	5
	2.2 Structure of the study number.....	5
3.	Electronic Patiënt Viewer .....	6
	3.1 Request ProMISe pharmacy account .....	6
	3.2 Username and password .....	6
	3.3 Login page.....	6
	3.4 Request new password.....	6
	3.5 Log in .....	7
	3.6 Change valid password .....	8
4.	View randomisation result .....	9
5.	Order study medication.....	10
6.	Receipt of medication.....	10
7.	Drug accountability .....	11
8.	Patiënt accountability.....	11
9.	Example (flag)labels study medication.....	12
	9.1 Labels (Dutch) .....	12
	9.2 French labels.....	13
10.	Additional explanation of the label .....	14
11.	Storage of medication .....	14
12.	Transport medication .....	14
13.	Deblinding.....	14
14.	Finance .....	14
15.	Contacts.....	14

## 1. Randomisation procedure




## 2. Randomisation

The local researcher/ PI in your hospital is, in collaboration with the central study coordinator of UZA, responsible for the randomisation of patients. If a patient has been randomized in your hospital, you will receive a confirmation email (i.e. randomisation email) with the study number (trialnumber/ randomisation number) and some other details about the patient.

### 2.1 Randomisation/ confirmation email

The randomisation email looks like this:



Dear Colleague,

Hereby we confirm that your patient, as specified below, complies with all the in- and exclusion criteria and is randomised in the ASPIRIN trial today.

Patient	
Center	////
Physician	////
Date of birth	////
Date of randomisation	////
Specific Questions at Randomisation	
Date of informed consent	////
Date of surgery	////
Subgroup	no adjuvant chemotherapy, pStage II
Gender	male
Age group	<70 years
Assigned Trialnumber	
Trialnumber	////

Note: this email does not show the randomisation result!

### 2.2 Structure of the study number

The study number of patients included in the ASPIRIN Trial is made up of a three-digit 'CenterID' (hospital number) and a four-digit 'PatientID' (patient number). The PatientID is an ascending number that is equal to the number of patients participating in the ASPIRIN Trial at your hospital, and is always an 8000-number. The first patient will always have number 8001 as PatientID, followed by patient 8002, 8003 etc.

### 3. Electronic Patiënt Viewer

After receiving the randomisation email, you can view the result - only as a pharmacist - using the Electronic Patient Viewer (EPV) in ProMISe. You need a pharmacy account for logging in.

#### 3.1 Request ProMISe pharmacy account


Requesting a pharmacy account can be done by sending an email to the central study coordinator ([aspirin@uza.be](mailto:aspirin@uza.be)). Please note that a signed task delegation log is required.

#### 3.2 Username and password

After your application has been approved, you will receive an email with a username that is linked to the email address you provided. You can then create a password via the login page.



#### 3.3 Login page

The ASPIRIN EPV on the ProMISe website is accessible via [www.msbi.nl](http://www.msbi.nl) > *Datamanagement* > *ProMISe* > *Projects* > *Datacenterheelkunde* > *ASPIRIN* > **Webform Facility (on the right of the screen)**  
[https://www.clinicalresearch.nl/PROMISE/S/HEIT/S\\_O\\_LUMC\\_C\\_HEELK\\_ASPIRIN\\_/LOGON/INDEX.HEI?MODE=1](https://www.clinicalresearch.nl/PROMISE/S/HEIT/S_O_LUMC_C_HEELK_ASPIRIN_/LOGON/INDEX.HEI?MODE=1)



#### 3.4 Request new password


On the login page you can create a password by clicking on *Renew password? Click here*. Then click on *obtain new password*.



In the next screen enter your username and click on *request security code*. You will now receive an email message with the security code.



Enter your username and security code (access code) as well as your new password and click on *confirm*.



Username  
Security code  
New Password  
Repeat New password


You can now use your new password.

### 3.5 Log in


On the login page you can log in with your username and password.

The ASPIRIN EPV on the ProMISe website is accessible via [www.msbi.nl](http://www.msbi.nl) > *Datamanagement* > *ProMISe* > *Projects* > *Datacenterheekunde* > *ASPIRIN* > **Webform Facility (on the right of the screen)**  
[https://www.clinicalresearch.nl/PROMISE/S/HEIT/S\\_O\\_LUMC\\_C\\_HEELK\\_ASPIRIN\\_/LOGON/INDEX.HEI?MODE=1](https://www.clinicalresearch.nl/PROMISE/S/HEIT/S_O_LUMC_C_HEELK_ASPIRIN_/LOGON/INDEX.HEI?MODE=1)

Enter your username and password and click on *show my webforms* and you will see the EPV in the screen.




Select *EPV* and then click on *Start Webform*.




### 3.6 Change valid password

Changing a valid password also takes place via the login page. Click on *Renew password? Click here* and then on *change valid password*.



The screenshot shows the ProMISe ASPIRIN login interface. It features a logo at the top left, followed by two input fields labeled 'username' and 'password'. Below these fields is a link that says 'Show my webforms' with a magnifying glass icon. At the bottom of the form area, there is a link 'Renew password? Click here' which is highlighted with a red rectangular box.



The screenshot shows the ProMISe Password Manager help page. The title is 'ProMISe Password Manager (Restart)'. There are navigation links for 'TOP' and 'Go to logon page'. A section titled 'How can we help you?' lists three questions: 'Do you want to specify a password for a new account?', 'Did you forget your password?', and 'Do you want to replace your (expired) password?'. The third question is followed by a button labeled 'change valid password', which is highlighted with a red rectangular box. Below this is a note: 'Please note that your username and password are strictly personal.' At the bottom, there is contact information for the help desk: 'HELPDESK: The general ProMISe help desk at ADM can be reached via email: ADM@lumc.nl; in urgent matters call +31 71 5269726'.

Then follow the steps on your screen.



#### 4. View randomisation result

After logging in, you will see an overview of the participating patients in your hospital with various data, including the randomisation result (allocated treatment).

Step 2: click on any icon below to display the data (n=18)

Center Id	Subject Id	Center	Date of birth	Age at randomisation	Trialnumber [auto-calculated]	Physician	Subgroup	Allocated treatment	Date of randomisation	Date of last study medication intake	Date of death
▶	8005	8016	DEMO city [Demo Randomisation only]	1940-04-02				Allocated treatment			
▶	8005	8015	DEMO city [Demo Randomisation only]	1920-03-01				Acetylsalicylic acid			
▶	8005	8014	DEMO city [Demo Randomisation only]	1920-01-01				Placebo			
▶	8005	8013	DEMO city [Demo Randomisation only]	1933-03-30				Acetylsalicylic acid			

By clicking on the icon next to CenterID, the EPV appears at the patient level. Then click on the plus sign next to *Record Locator* to expand the record.

- Record Locator
 

- Patient [8005] 8016
  - + Record

You will now see the EPV at the patient level. With the printer icon you can also print this patient specific overview.

- Record Locator
 

- Patient [8005] 8016
  - Record
 

Center Id	8005	DEMO city [Demo Randomisation only]
Subject Id	8016	
Center	8005	DEMO city [Demo Randomisation only]
Date of birth	1940/04/02	
Age at randomisation	74	
Physician	2341	G.J. Liefers



## 7. Drug accountability

The medication is delivered in boxes of 16 containers containing about 100 tablets each. The size of these boxes is 17x17x10 cm.

You will receive 2 different containers from the courier service; placebo and verum. For the pharmacy, the medication is therefore deblinded.

At the time you prepare the study medication for a study patient, you write the *Subject n°* (= Subject ID / study number/ trial number), visit number, date of birth, and the name of the local investigator on the container. Part of the label is a flag label (deductible). Before you release the study medication, remove the flag label of the container, with this you will **blind the medication**. The medication number is on both parts of the label, which makes it possible to trace which medication the patient has received.

You must keep the drug accountability on a form. An example of the drug accountability form is included with the initiation visit. You store the flag label on / at the drug accountability form.

The medication is issued the first two years once every six months (= 2 pots), then once a year (= 4 pots).

## 8. Patient accountability

The patients do not have to keep accountability and the pharmacy also plays no role in this. Patient compliance is questioned by the local research physician. The residual medication may be destroyed by the local researcher or the local pharmacy.

## 9. Example (flag)labels study medication

### 9.1 Labels (Dutch)

#### Label aspirine

R.A. 20 APR. 2017

Aspirin trial  
EudraCT nummer: 2011-004686-32

Subject nr:.....                      Geboortedatum:.....  
 Visite nr:.....                      Medicatie nummer: XXXXXXXX  
 100 tabl. Acetylsalicylzuur 80 mg of Placebo voor oraal gebruik  
 Gebruik: Dagelijks 1 tablet innemen volgens protocol  
 Onderzoeker: .....

Lot nr: XXXXXXXX      Hertestdatum: 11-1111

Bewaren bij 15-25°C. Beschermen tegen licht en vocht  
 Uitsluitend bestemd voor klinisch onderzoek  
 Buiten het zicht en bereik van kinderen bewaren

Sponsor: Leids Universitair Medisch Centrum, Albinusdreef 2, 2333 ZA Leiden

Aspirin trial  
 EudraCT nummer: 2011-004686-32  
 Medicatie nummer: XXXXXXXX  
 100 tabletten Acetylsalicylzuur 80mg  
 Lot nr: xxxxxx      Hertestdatum: 11-1111  
 00000

S.L. Kochen 20 APR. 2017

**Complete**                      **Remove label before handing over !**

#### Label placebo

R.A. 20 APR. 2017

Aspirin trial  
EudraCT nummer: 2011-004686-32

Subject nr:.....                      Geboortedatum:.....  
 Visite nr:.....                      Medicatie nummer: XXXXXXXX  
 100 tabl. Acetylsalicylzuur 80 mg of Placebo voor oraal gebruik  
 Gebruik: Dagelijks 1 tablet innemen volgens protocol  
 Onderzoeker: .....

Lot nr: XXXXXXXX      Hertestdatum: 11-1111

Bewaren bij 15-25°C. Beschermen tegen licht en vocht  
 Uitsluitend bestemd voor klinisch onderzoek  
 Buiten het zicht en bereik van kinderen bewaren

Sponsor: Leids Universitair Medisch Centrum, Albinusdreef 2, 2333 ZA Leiden

Aspirin trial  
 EudraCT nummer: 2011-004686-32  
 Medicatie nummer: XXXXXXXX  
 100 tabletten PLACEBO Acetylsalicylzuur 80mg  
 Lot nr: xxxxxx      Hertestdatum: 11-1111  
 00000

S.L. Kochen 20 APR. 2017

## 9.2 French labels

### Label Asprine

Aspirin trial  
 Subject n°: ..... Visite n°:.....  
 Date de naissance: .....

100 comprimés de l'Acide acétylsalicylique 80 mg ou placebo à usage oral

Utilisation: 1 comprimé par jour selon le protocole

Chercheur: .....

Aspirin Trial  
 Eudract n°: xxxxxx  
 Numéro de la médication: xxxxxxxx  
 100 comprimés de l'Acide acétylsalicylique 80 mg  
 Lot n° : xxxxxx      Date test de répétabilité: xx-xxxx

Lot n° : xxxxxxxxxx      Date test de répétabilité: xx-xxxx

Conserver à 15-25°C. Protéger de la lumière et de l'humidité.  
 Exclusivement pour la recherche clinique.  
 Conserver hors de la vue et de la portée des enfants.

Sponsor: Universitair Ziekenhuis Antwerpen  
 Wilrijkstraat 10, 2650 Edegem, Belgique

Numéro de la médication: xxxxxxxxxx

**COMPLETE**

**REMOVE LABEL BEFORE HANDING OVER!**

### Label Placebo

Aspirin trial  
 Subject n°: ..... Visite n°:.....  
 Date de naissance: .....

100 comprimés de l'Acide acétylsalicylique 80 mg ou placebo à usage oral

Utilisation: 1 comprimé par jour selon le protocole

Chercheur: .....

Aspirin Trial  
 Eudract n°: xxxxxx  
 Numéro de la médication: xxxxxxxx  
 100 comprimés PLACEBO Acide acétylsalicylique 80 mg  
 Lot n° : xxxxxx      Date test de répétabilité: xx-xxxx

Lot n° : xxxxxxxxxx      Date test de répétabilité: xx-xxxx

Conserver à 15-25°C. Protéger de la lumière et de l'humidité.  
 Exclusivement pour la recherche clinique.  
 Conserver hors de la vue et de la portée des enfants.

Sponsor: Universitair Ziekenhuis Antwerpen  
 Wilrijkstraat 10, 2650 Edegem, Belgique

Numéro de la médication: xxxxxxxxxx

## 10. Additional explanation of the label

**Subject n°** = Trial number = randomisation number = study number ( . . . 8 . . . )

**Visit n°** = this number normally corresponds to the number of times the patient has received his study medication, and thus also with the number of the study visit.

## 11. Storage of medication

The study medication must be stored separately from non-study medication. The medication should be stored at room temperature (see study medication label) and the temperature should be monitored. Temperature excursions (<15°C or >25°C) of more than 30 minutes must be reported to the central study coordinator (see contact details at the bottom of this page).

## 12. Transport medication

If medication is transported outside the regular monitored storage, the temperature of the product must be monitored. An exception applies to transport shorter than 30 minutes if this is a one-off. If you have transported medication unmonitored for more than 30 minutes, you must report this. This only applies before the medication has been handed over to the patient.

## 13. Deblinding

Due to the minimal risk of life-threatening events, deblinding takes place within office hours. The local investigator must first have permission from the central study coordinator of the Antwerp University Hospital before he can approach the local hospital pharmacist for deblinding. You must consult the EPV for carrying out the deblinding.

## 14. Finance

The pharmacy receives no reimbursement for the start-up and issuing of the medication.

## 15. Contacts

Contact persons at the Antwerp University Hospital

Principal investigator: Prof. dr. Marc Peeters, head of the oncology department  
E-mail: [marc.peeters@uza.be](mailto:marc.peeters@uza.be)

Central study coordinator: Marjon De Roose  
E-mail: [aspirin@uza.be](mailto:aspirin@uza.be)  
Telephone number: +32 3 821 40 82